Bunko H
Department of Medical Informatics, Kanzawa University Hospital.
Kaku Igaku. 1994 Aug;31(8):1005-10.
In the field of nuclear cardiology, 99mTc labeled myocardial perfusion agents such as MIBI, Tetrofosmin and Teboroxime, 111In-antimyosin for imaging of myocardial necrosis, 123I-betamethyl-iodophenylpentadecanoic acid (BMIPP) for imaging of myocardial fatty acid metabolism and 123I-metaiodobenzylguanidine (MIBG) for imaging of myocardial adrenergic function are introduced recently in Japan. Improved image quality and simultaneous evaluation of myocardial perfusion, function and wall motion can be obtained with use of 99mTc labeled myocardial perfusion agents. 111In-antimyosin enables specific imaging of myocardial necrosis which leads to the use for wide variety of heart diseases. Discrepancy of the myocardial perfusion and metabolism in case of stunned myocardium or cardiomyopathy can be evaluated by 123I-BMIPP in conjunction with perfusion agent. Recently wide variety of diseases which may have cardiac adrenergic abnormality are targeted for 123I-MIBG imaging. These new radiopharmaceuticals are expected to be powerful tool for evaluation of the pathophysiology including severity and prognosis and evaluation of the etiology of the various heart diseases.
在核心脏病学领域，诸如甲氧基异丁基异腈（MIBI）、替曲膦和特博肟等99mTc标记的心肌灌注剂、用于心肌坏死显像的111In-抗肌凝蛋白、用于心肌脂肪酸代谢显像的123I-β-甲基-碘代苯基十五烷酸（BMIPP）以及用于心肌肾上腺素能功能显像的123I-间碘苄胍（MIBG）最近在日本被引入。使用99mTc标记的心肌灌注剂能够获得更高的图像质量，并能同时评估心肌灌注、功能和室壁运动。111In-抗肌凝蛋白能够对心肌坏死进行特异性显像，从而可用于多种心脏病的诊断。联合灌注剂使用123I-BMIPP能够评估心肌顿抑或心肌病时心肌灌注与代谢的差异。最近，123I-MIBG显像针对的是多种可能存在心脏肾上腺素能异常的疾病。这些新型放射性药物有望成为评估包括严重程度和预后在内的病理生理学以及评估各种心脏病病因的有力工具。
